Enzo Total Current Assets vs Cash Analysis
ENZ Stock | USD 1.07 0.02 1.90% |
Enzo Biochem financial indicator trend analysis is much more than just examining Enzo Biochem latest accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Enzo Biochem is a good investment. Please check the relationship between Enzo Biochem Total Current Assets and its Cash accounts. Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Enzo Biochem. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in board of governors. For more information on how to buy Enzo Stock please use our How to Invest in Enzo Biochem guide.
Total Current Assets vs Cash
Total Current Assets vs Cash Correlation Analysis
The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Enzo Biochem Total Current Assets account and Cash. At this time, the significance of the direction appears to have very strong relationship.
The correlation between Enzo Biochem's Total Current Assets and Cash is 0.81. Overlapping area represents the amount of variation of Total Current Assets that can explain the historical movement of Cash in the same time period over historical financial statements of Enzo Biochem, assuming nothing else is changed. The correlation between historical values of Enzo Biochem's Total Current Assets and Cash is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Total Current Assets of Enzo Biochem are associated (or correlated) with its Cash. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Cash has no effect on the direction of Total Current Assets i.e., Enzo Biochem's Total Current Assets and Cash go up and down completely randomly.
Correlation Coefficient | 0.81 |
Relationship Direction | Positive |
Relationship Strength | Strong |
Total Current Assets
The total value of all assets that are expected to be converted into cash within one year or during the normal operating cycle.Cash
Cash refers to the most liquid asset of Enzo Biochem, which is listed under current asset account on Enzo Biochem balance sheet and usually includes currency, coins, checking accounts, and not deposited checks received from Enzo Biochem customers. The amounts must be unrestricted with restricted cash listed in a different Enzo Biochem account. The total amount of money in the form of currency that a company has in its possession. This includes all bills, coins, and funds in bank accounts.Most indicators from Enzo Biochem's fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Enzo Biochem current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Enzo Biochem. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in board of governors. For more information on how to buy Enzo Stock please use our How to Invest in Enzo Biochem guide.At this time, Enzo Biochem's Selling General Administrative is fairly stable compared to the past year. Discontinued Operations is likely to rise to about 54.7 M in 2024, whereas Sales General And Administrative To Revenue is likely to drop 0.59 in 2024.
2021 | 2022 | 2023 | 2024 (projected) | Gross Profit | 42.0M | 11.6M | 13.3M | 12.6M | Total Revenue | 107.1M | 31.1M | 35.7M | 63.8M |
Enzo Biochem fundamental ratios Correlations
Click cells to compare fundamentals
Enzo Biochem Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Enzo Biochem fundamental ratios Accounts
2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
Total Assets | 112.5M | 113.7M | 95.9M | 121.9M | 140.2M | 100.7M | |
Short Long Term Debt Total | 32.8M | 22.7M | 20.6M | 7.0M | 6.3M | 6.0M | |
Other Current Liab | 10.3M | 11.6M | 12.3M | 21.1M | 24.3M | 25.5M | |
Total Current Liabilities | 32.8M | 26.1M | 24.6M | 40.0M | 46.0M | 48.3M | |
Total Stockholder Equity | 58.4M | 68.6M | 54.5M | 78.5M | 90.2M | 75.1M | |
Property Plant And Equipment Net | 34.4M | 33.6M | 32.4M | 16.7M | 19.2M | 12.3M | |
Net Debt | (15.1M) | 9.2M | (1.0M) | (75.4M) | (67.8M) | (64.4M) | |
Retained Earnings | (278.3M) | (270.4M) | (288.6M) | (268.4M) | (241.5M) | (229.4M) | |
Cash | 47.9M | 13.5M | 21.6M | 82.4M | 94.7M | 99.5M | |
Non Current Assets Total | 43.8M | 43.1M | 41.5M | 23.4M | 26.9M | 32.4M | |
Non Currrent Assets Other | 1.4M | 1.8M | 1.6M | 1.7M | 1.5M | 1.5M | |
Cash And Short Term Investments | 47.9M | 43.5M | 21.6M | 82.4M | 94.7M | 99.5M | |
Net Receivables | 9.1M | 10.2M | 11.5M | 4.8M | 5.5M | 5.3M | |
Common Stock Shares Outstanding | 47.7M | 48.3M | 48.6M | 49.2M | 56.5M | 36.9M | |
Liabilities And Stockholders Equity | 112.5M | 113.7M | 95.9M | 121.9M | 140.2M | 100.7M | |
Non Current Liabilities Total | 21.4M | 19.0M | 16.8M | 3.4M | 3.1M | 2.9M | |
Inventory | 7.8M | 12.7M | 15.4M | 7.9M | 9.1M | 5.6M | |
Other Current Assets | 4.0M | 4.2M | 5.8M | 2.3M | 2.7M | 2.8M | |
Other Stockholder Equity | 334.5M | 337.1M | 339.5M | 344.4M | 396.1M | 215.7M | |
Total Liab | 54.2M | 45.1M | 41.4M | 43.4M | 39.1M | 41.0M | |
Property Plant And Equipment Gross | 34.4M | 33.6M | 63.9M | 34.0M | 39.1M | 41.0M | |
Total Current Assets | 68.8M | 70.6M | 54.4M | 98.5M | 113.2M | 68.3M | |
Accumulated Other Comprehensive Income | 1.7M | 1.4M | 3.2M | 1.9M | 2.2M | 2.3M | |
Intangible Assets | 1.0M | 538K | 244K | 7.5M | 6.7M | 6.7M | |
Accounts Payable | 8.5M | 8.1M | 8.5M | 3.6M | 4.1M | 5.0M | |
Short Term Debt | 11.5M | 3.7M | 3.7M | 3.6M | 3.2M | 3.5M | |
Common Stock Total Equity | 476K | 479K | 485K | 487K | 560.1K | 422.6K | |
Common Stock | 479K | 485K | 487K | 499K | 573.9K | 427.7K | |
Other Assets | 1.4M | 1.8M | 1.6M | 6.7M | 6.0M | 6.3M | |
Property Plant Equipment | 14.5M | 33.6M | 17.3M | 16.7M | 19.2M | 10.2M | |
Current Deferred Revenue | (391K) | 2.5M | 2.7M | 11.7M | 13.5M | 14.2M | |
Long Term Debt | 4.5M | 4.4M | 4.1M | 269K | 309.4K | 293.9K | |
Net Tangible Assets | 50.4M | 60.9M | 47.0M | 78.5M | 90.2M | 58.6M | |
Retained Earnings Total Equity | (252.2M) | (249.7M) | (278.3M) | (288.6M) | (259.8M) | (272.8M) | |
Capital Surpluse | 334.5M | 337.1M | 339.5M | 344.4M | 396.1M | 359.7M | |
Non Current Liabilities Other | 424K | 16.9M | 5K | 12.8M | 14.7M | 15.4M | |
Short Long Term Debt | 7.1M | 152K | 229K | 2.6M | 2.3M | 1.5M |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.MSFT | Microsoft | |
GM | General Motors | |
CRM | Salesforce |
Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Enzo Biochem. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in board of governors. For more information on how to buy Enzo Stock please use our How to Invest in Enzo Biochem guide.You can also try the Earnings Calls module to check upcoming earnings announcements updated hourly across public exchanges.
Complementary Tools for Enzo Stock analysis
When running Enzo Biochem's price analysis, check to measure Enzo Biochem's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Enzo Biochem is operating at the current time. Most of Enzo Biochem's value examination focuses on studying past and present price action to predict the probability of Enzo Biochem's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Enzo Biochem's price. Additionally, you may evaluate how the addition of Enzo Biochem to your portfolios can decrease your overall portfolio volatility.
Money Flow Index Determine momentum by analyzing Money Flow Index and other technical indicators | |
Price Transformation Use Price Transformation models to analyze the depth of different equity instruments across global markets | |
Stock Tickers Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites | |
Insider Screener Find insiders across different sectors to evaluate their impact on performance | |
Risk-Return Analysis View associations between returns expected from investment and the risk you assume | |
Pair Correlation Compare performance and examine fundamental relationship between any two equity instruments | |
Technical Analysis Check basic technical indicators and analysis based on most latest market data | |
Aroon Oscillator Analyze current equity momentum using Aroon Oscillator and other momentum ratios | |
Portfolio Optimization Compute new portfolio that will generate highest expected return given your specified tolerance for risk |
Is Enzo Biochem's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Enzo Biochem. If investors know Enzo will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Enzo Biochem listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.47) | Revenue Per Share 0.657 | Quarterly Revenue Growth 0.138 | Return On Assets (0.17) | Return On Equity (0.45) |
The market value of Enzo Biochem is measured differently than its book value, which is the value of Enzo that is recorded on the company's balance sheet. Investors also form their own opinion of Enzo Biochem's value that differs from its market value or its book value, called intrinsic value, which is Enzo Biochem's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Enzo Biochem's market value can be influenced by many factors that don't directly affect Enzo Biochem's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Enzo Biochem's value and its price as these two are different measures arrived at by different means. Investors typically determine if Enzo Biochem is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Enzo Biochem's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.